Accomplish
Páginas: 2 (464 palabras)
Publicado: 15 de abril de 2011
new england journal of medicine
The
established in 1812
december 4, 2008
vol. 359
no. 23
Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk PatientsKenneth Jamerson, M.D., Michael A. Weber, M.D., George L. Bakris, M.D., Björn Dahlöf, M.D., Bertram Pitt, M.D., Victor Shi, M.D., Allen Hester, Ph.D., Jitendra Gupte, M.S., Marjorie Gatlin, M.D., and EricJ. Velazquez, M.D., for the AccoMPLiSH trial investigators*
A bs t r ac t
Background
The optimal combination drug therapy for hypertension is not established, although current U.S. guidelinesrecommend inclusion of a diuretic. We hypothesized that treatment with the combination of an angiotensin-converting–enzyme (ACE) inhibitor and a dihydropyridine calcium-channel blocker would be moreeffective in reducing the rate of cardiovascular events than treatment with an ACE inhibitor plus a thiazide diuretic.
Methods
In a randomized, double-blind trial, we assigned 11,506 patients withhypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide. The primary end point was the compositeof death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization.
ResultsFrom the University of Michigan Health System, Ann Arbor (K.J., B.P.); the State University of New York Downstate Medical college, Brooklyn (M.A.W.); the University of chicago Pritzker School ofMedicine, chicago (G.L.B.); Sahlgrenska University Hospital, Gothenburg, Sweden (B.D.); Novartis Pharmaceuticals, East Hanover, NJ (V.S., A.H., J.G., M.G.); and Duke University School of Medicine, Durham,Nc (E.J.V.). Address reprint requests to Dr. Jamerson at the Division of cardiovascular Medicine, University of Michigan Health System, 24 Frank Lloyd Wright Dr., Lobby M, Ann Arbor, Mi 48106, or at...
The
established in 1812
december 4, 2008
vol. 359
no. 23
Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk PatientsKenneth Jamerson, M.D., Michael A. Weber, M.D., George L. Bakris, M.D., Björn Dahlöf, M.D., Bertram Pitt, M.D., Victor Shi, M.D., Allen Hester, Ph.D., Jitendra Gupte, M.S., Marjorie Gatlin, M.D., and EricJ. Velazquez, M.D., for the AccoMPLiSH trial investigators*
A bs t r ac t
Background
The optimal combination drug therapy for hypertension is not established, although current U.S. guidelinesrecommend inclusion of a diuretic. We hypothesized that treatment with the combination of an angiotensin-converting–enzyme (ACE) inhibitor and a dihydropyridine calcium-channel blocker would be moreeffective in reducing the rate of cardiovascular events than treatment with an ACE inhibitor plus a thiazide diuretic.
Methods
In a randomized, double-blind trial, we assigned 11,506 patients withhypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide. The primary end point was the compositeof death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization.
ResultsFrom the University of Michigan Health System, Ann Arbor (K.J., B.P.); the State University of New York Downstate Medical college, Brooklyn (M.A.W.); the University of chicago Pritzker School ofMedicine, chicago (G.L.B.); Sahlgrenska University Hospital, Gothenburg, Sweden (B.D.); Novartis Pharmaceuticals, East Hanover, NJ (V.S., A.H., J.G., M.G.); and Duke University School of Medicine, Durham,Nc (E.J.V.). Address reprint requests to Dr. Jamerson at the Division of cardiovascular Medicine, University of Michigan Health System, 24 Frank Lloyd Wright Dr., Lobby M, Ann Arbor, Mi 48106, or at...
Leer documento completo
Regístrate para leer el documento completo.